| Literature DB >> 6798760 |
Abstract
Prothrombin complex concentrates prepared for clinical use are reviewed with emphasis on frequently observed adverse reactions such as viral hepatitis and thromboembolic complications. Preparation procedures and quality control are described briefly, and the use of these concentrates in the treatment of hemophilia A patients who develop factor VIII inhibitors is also described. The causes of and methods for the detection of potential thrombogenicity are discussed and suggestions which may result in a safer product are made.Entities:
Mesh:
Substances:
Year: 1981 PMID: 6798760 DOI: 10.1111/j.1423-0410.1981.tb01048.x
Source DB: PubMed Journal: Vox Sang ISSN: 0042-9007 Impact factor: 2.144